<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763969</url>
  </required_header>
  <id_info>
    <org_study_id>IM016-006</org_study_id>
    <nct_id>NCT02763969</nct_id>
  </id_info>
  <brief_title>Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986202 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of BMS-986202 in Subjects With Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish if BMS-986202 is safe and effective at treating
      autoimmune diseases such as psoriasis. BMS-986202 which has shown some promise in preclinical
      studies for inhibiting autoimmune conditions such as psoriasis. This study will be the first
      time this drug is given to humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2016</start_date>
  <completion_date type="Actual">December 15, 2016</completion_date>
  <primary_completion_date type="Actual">December 15, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of a single oral dose of BMS-986202 based on number of incidence of AEs, SAEs, AEs leading to discontinuation or death, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations</measure>
    <time_frame>4 weeks after the start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of a multiple oral dose of BMS-986202 based on number of incidence of AE, SAEs, AEs leading to discontinuation or death, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations</measure>
    <time_frame>4 weeks after the start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the psoriasis area</measure>
    <time_frame>4 weeks after the start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity index (PASI) score</measure>
    <time_frame>4 weeks after the start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-986202 on electrocardiographic (ECG) parameters such as heart rate in healthy subjects of any ethnic background (Parts A, B, C, D)</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-986202 on electrocardiographic (ECG) parameters such as PR interval in healthy subjects of any ethnic background (Parts A, B, C, D)</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>The interval from the beginning of the P wave to the beginning of the QRS complex (PR interval)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-986202 on electrocardiographic (ECG) parameters such as QRS interval in healthy subjects of any ethnic background (Parts A, B, C, D)</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>The interval from the beginning of the Q wave and the end of the S wave (QRS interval)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-986202 on electrocardiographic (ECG) parameters such as QTc interval in healthy subjects of any ethnic background (Parts A, B, C, D)</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>The interval from the beginning of the Q wave to the end of the T wave (QT interval).
The QT interval corrected for heart rate (QTc interval)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of multiple oral doses of BMS-986202 in subjects with moderate to severe psoriasis (Part E)</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>Safety of multiple oral doses of BMS-986202 in subjects with moderate to severe psoriasis (Part E) based on number of incidence of adverse events(AEs), serious adverse events(SAEs), AEs leading to discontinuation or death, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Part A: Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986202 or Placebo specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986202 or Placebo + Interferon alpha-2a recombinant specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Multiple Ascending Dose-Japanese descent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986202 or Placebo specified dose on specified days in patients of Japanese descent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: Relative Bioavailability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986202 (Liquid) or BMS-986202 (Capsule) + Famotidine specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: Proof of Mechanism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986202 or Placebo + Ustekinumab specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986202</intervention_name>
    <arm_group_label>Part A: Single Ascending Dose</arm_group_label>
    <arm_group_label>Part B: Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Part C: Multiple Ascending Dose-Japanese descent</arm_group_label>
    <arm_group_label>Part D: Relative Bioavailability</arm_group_label>
    <arm_group_label>Part E: Proof of Mechanism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part A: Single Ascending Dose</arm_group_label>
    <arm_group_label>Part B: Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Part C: Multiple Ascending Dose-Japanese descent</arm_group_label>
    <arm_group_label>Part E: Proof of Mechanism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alpha-2a recombinant</intervention_name>
    <arm_group_label>Part B: Multiple Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <arm_group_label>Part D: Relative Bioavailability</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <arm_group_label>Part E: Proof of Mechanism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy Male and Female participants

          -  18 to 50 years of age (Parts A-D)

          -  18 to 70 years of age (Part E)

          -  Diagnosed with plaque psoriasis (Part E)

        Exclusion Criteria:

          -  Participants that had recent infections

          -  Participants with Low Blood Pressure

          -  Participants with any heart related problems

          -  Participants with cancer

          -  Participants with any other major medical illness

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

